Your browser doesn't support javascript.
loading
Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group.
Sclafani, Francesco; Fontana, Elisa; Wyrwicz, Lucjan; Wagner, Anna Dorothea; Valle, Juan W; Smyth, Elizabeth; Peeters, Mark; Obermannova, Radka; Neuzillet, Cindy; Lutz, Manfred P; Koessler, Thibaud; Ben-Aharon, Irit; Arnold, Dirk; Alsina, Maria; Moehler, Markus.
Afiliación
  • Sclafani F; Department of Medical Oncology, Institut Jules Bordet, Rue Meylemeersch 90, Anderlecht 1070, Belgium; Université Libre de Bruxelles (ULB), Brussels, Belgium; European Organisation for Research and Treatment of Cancer, Brussel, Belgium. Electronic address: francesco.sclafani@bordet.be.
  • Fontana E; European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Sarah Cannon Research Institute, London, UK.
  • Wyrwicz L; European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
  • Wagner AD; European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Department of Oncology, Division of medical Oncology, Lausanne University Hospital (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
  • Valle JW; European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Division of Cancer Sciences, University of Manchester, Manchester, UK; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
  • Smyth E; European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK.
  • Peeters M; European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Department of Oncology, Universitair Ziekenhuis Antwerpen, Antwerp, Belgium.
  • Obermannova R; European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech
  • Neuzillet C; European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Department of Medical Oncology, Institut Curie, Versailles Saint-Quentin University - Paris Saclay University, Saint-Cloud, France.
  • Lutz MP; European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Caritasklinikum, Saarbrucken, Germany.
  • Koessler T; European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Department of Oncology, Geneva University Hospital, Geneva, Switzerland; Swiss Cancer Center Leman (SCCL), University of Geneva, Lausanne, Switzerland.
  • Ben-Aharon I; European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Division of Oncology, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion, Haifa, Israel.
  • Arnold D; European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Department of Oncology, Haematology and Palliative Care, AK Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany.
  • Alsina M; European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Passeig de la Vall d'Hebron, Barcelona, Spain.
  • Moehler M; European Organisation for Research and Treatment of Cancer, Brussel, Belgium; Department of Internal Medicine, Johannes-Gutenberg University, Mainz, Germany.
Clin Colorectal Cancer ; 21(3): 188-197, 2022 09.
Article en En | MEDLINE | ID: mdl-35637095
Recently, we have witnessed impressive diagnostic and therapeutic changes for gastrointestinal cancer patients. New challenges brought by the COVID-19 pandemic have led us to re-evaluate our work priorities. Thanks to the commendable resilience of both investigators and patients, however, clinical research never stopped. In addition to conducting cutting-edge research and serving patients' needs, as EORTC Gastrointestinal Tract Cancer Group, we are committed to pursuing educational initiatives beneficial to the entire European oncology community and beyond. In this regard, we have been providing critical discussions of new data from major international meetings. In this article, we discuss results of important selected studies presented at the 2022 ASCO Gastrointestinal Cancer Symposium, putting them in perspectives and highlighting potential implications for routine practice. With the number of in-person attendees and practice-changing/informing trials presented, this meeting represented a milestone in the return to normality as well as in the fight against cancer.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gastrointestinales / COVID-19 Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Clin Colorectal Cancer Asunto de la revista: GASTROENTEROLOGIA / NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Gastrointestinales / COVID-19 Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Clin Colorectal Cancer Asunto de la revista: GASTROENTEROLOGIA / NEOPLASIAS Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos